Fast Results

Turnaround time:
Two weeks or less

Better Coverage

FDA-approved with
Medicare coverage

Accurate Answers

Industry leading and independently
verified lab accuracy

FDA-Approved Targeted Therapies

  • BREAST
  • ovarian

TUMOR TYPE

BIOMARKER

Deleterious or suspected delerious mutations in BRCA1 and BRCA2 genes

FDA APPROVED THERAPY

LYNPARZA® (OLAPARIB)
TALZENNA™ (TALAZOPARIB)

BIOMARKER

Deleterious or suspected delerious mutations in BRCA1 and BRCA2 genes

FDA APPROVED THERAPY

LYNPARZA® (OLAPARIB)
RUBRACA® (RUCAPARIB)

The Importance of Variant Classification

43-63% of germline BRCA mutations identified as VUSs at competing labs can be definitively classified using Myriad’s variant classification program1.

Myriad has over 25 years of experience in variant classification of BRAC1/2. The resulting analysis and interpretation of the variants reduces VUS in genetic test results and provides confidence for oncologists when determining the appropriate therapy for their patients.

We understand that you need your patients’ germline BRCA1/2 status quickly to minimize your patients’ anxiety while they wait for a result and to get them on treatment. BRACAnalysis CDx can report your patients’ germline BRCA1/2 status in less than two weeks after we receive the sample.

Sources:

  1. Gradishar W, et al. Clinical variant classification: a comparison of public databases and a commercial testing laboratory. Oncologist. 2017;22(7):797-803.